ABSTRACT
Purpose: To describe the case of an elderly man who was incidentally found to have multiple hypopigmented choroidal lesions in the left eye in the absence of intraocular inflammation. Methods: A case report was analyzed, including the laboratory workup and imaging results. Results: The workup for conditions, including birdshot chorioretinopathy, syphilis, and tuberculosis, were negative. Ancillary imaging confirmed a diagnosis of uveal lymphoid hyperplasia (ULH). The patient was stable under observation for more than 1 year. Conclusions: Careful examination and imaging findings can aid in differentiating between ULH and other diagnoses.
ABSTRACT
A 5-year-old boy had subacute painless visual loss in his left eye with disk edema, macular edema, and choroidal thickening. He was subsequently diagnosed with inflammatory papillitis and choroiditis from Crohn's disease. The disk and macular edema responded minimally to antivascular endothelial growth factor injections but significantly to intravitreal corticosteroids.
Subject(s)
Choroiditis , Crohn Disease , Papilledema , Angiogenesis Inhibitors/therapeutic use , Child , Child, Preschool , Choroiditis/diagnosis , Choroiditis/drug therapy , Crohn Disease/complications , Crohn Disease/diagnosis , Crohn Disease/drug therapy , Humans , Intravitreal Injections , Male , Papilledema/diagnosis , Papilledema/drug therapy , Papilledema/etiology , Vascular Endothelial Growth Factor AABSTRACT
Purpose: To report the outcomes in eyes with noninfectious uveitis receiving dexamethasone implant at the time of pars plana vitrectomy (PPV).Methods: Retrospective analysis of visual acuity (VA), intraocular pressure (IOP), vitreous haze score (VHS), and central subfield thickness (CST) at baseline and follow-up visits.Results: Fourteen eyes received dexamethasone implant at the time of PPV. The CST was improved from 469 ± 182 µm at baseline to 320 ± 60 at 6 months (p = .0112) and 295 ± 46 at 12 months (p = .0728). Vitritis only recurred in 2 eyes at 6 months (18.2%) and 1 eye at 12 months (14.3%). The probability of VA improvement of ≥0.3 logMAR was 57% at 6 months and 66% at 12 months. Therapy for IOP rise was initiated in 6 eyes (42.9%).Conclusions: Local delivery of dexamethasone implant with PPV is a feasible method to counteract postoperative inflammation and macular thickening.
Subject(s)
Dexamethasone/administration & dosage , Drug Implants , Glucocorticoids/administration & dosage , Panuveitis/drug therapy , Vitrectomy , Adult , Aged , Aged, 80 and over , Diabetic Retinopathy/surgery , Epiretinal Membrane/surgery , Female , Humans , Intraocular Pressure/physiology , Intravitreal Injections , Male , Middle Aged , Panuveitis/diagnostic imaging , Panuveitis/physiopathology , Phacoemulsification , Retinal Vein Occlusion/surgery , Retrospective Studies , Tomography, Optical Coherence , Treatment Outcome , Visual Acuity/physiologySubject(s)
Candidiasis/pathology , Endophthalmitis/microbiology , Eye Infections, Fungal/microbiology , Adult , Candida/isolation & purification , Candidiasis/etiology , Endophthalmitis/pathology , Eye Infections, Fungal/complications , Eye Infections, Fungal/pathology , Hepatitis C/complications , Humans , Male , Ophthalmoscopy , Substance Abuse, Intravenous/complicationsABSTRACT
PURPOSE: We aimed to evaluate the association between diabetic status and the rates of cataract extraction (CE) following pars plana vitrectomy (PPV). DESIGN: Retrospective cohort, multicenter database study. PARTICIPANTS: Patients were selected from an insurance claims database (PharMetrics LifeLink) that included persons who had filed claims between 2006 and 2015 in the United States. METHODS: We analyzed the records of 22 146 patients who underwent PPV performed by 2705 retina physicians. The vitrectomy group included patients ≥18 years of age who had undergone PPV. The control group included patients who were matched to the vitrectomy group 1:2 based on sex, diabetes mellitus (DM) status, region of the United States, and Charleston Comorbidity Index. MAIN OUTCOME MEASURES: Hazard ratios (HRs) and rates of cataract surgery in patients with and without diabetes who had undergone prior PPV. RESULTS: The hazard ratio for post-PPV CE was lower among patients with diabetes (3.307; 95% confidence interval [CI], 3.051-3.583) than among patients without diabetes (4.889; 95% CI, 4.670-5.119). This association was significant for all subgroups of patients with diabetes except in patients with diabetes and without retinopathy (4.086; 95% CI, 3.511-4.754). There was a significantly longer time between PPV and CE in patients with diabetes (537 days; 95% CI, 459-677 days) compared with those without diabetes (295 days; 95% CI, 278-312 days). The type of DM (type 1 vs. type 2) did not influence the rate of post-PPV cataract surgery. In persons with diabetes who underwent PPV, we observed a trend for a lower HR of cataract surgery in eyes with proliferative retinopathy (0.903; 95% CI, 0.725-1.124), and nonproliferative retinopathy (0.965; 95% CI, 0.721-1.290) compared with eyes with no retinopathy. CONCLUSIONS: Eyes of patients with diabetes had a significantly decreased risk of undergoing CE after PPV surgery compared with eyes of patients without diabetes.
Subject(s)
Cataract Extraction , Cataract/complications , Diabetic Retinopathy/surgery , Visual Acuity , Vitrectomy/methods , Adolescent , Adult , Aged , Aged, 80 and over , Diabetic Retinopathy/complications , Diabetic Retinopathy/diagnosis , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Young AdultABSTRACT
The mitogen-activated kinase pathway plays an important role in cell survival, and its dysregulation is associated with cancers such as melanoma. Drugs designed to target this pathway have been associated with serous retinal detachments in a new entity termed MEK inhibitor-associated retinopathy (MEKAR). MEKAR has classically been described as self-limiting, with serous fluid often resolving without discontinuation of the drug. We present a case in which a patient undergoing treatment for metastatic melanoma with lacnotuzumab, a macrophage colony-stimulating factor inhibitor that blocks an upstream component of the mitogen-activated protein kinase pathway, developed serous retinopathy that did not resolve despite drug discontinuation.
Subject(s)
Face/pathology , Xanthogranuloma, Juvenile/diagnosis , Female , Humans , Infant , Xanthogranuloma, Juvenile/pathologyABSTRACT
PURPOSE: To report the successful utilization of adjunctive repeat intravitreal corticosteroid therapy for the treatment of cystoid macular edema in syphilis-related uveitis. METHODS/PATIENTS: An HIV-positive patient with treated ocular syphilis who developed refractory cystoid macular edema (CME) was treated with repeat intravitreal corticosteroid therapy including dexamethasone intravitreal implants. RESULTS: Treatment led to the resolution of CME and improvement in visual acuity. CONCLUSIONS: Intravitreal corticosteroid therapy may be a viable adjunctive treatment for refractory CME in patients with treated syphilitic uveitis. Corticosteroid-induced exacerbation of infection is unlikely in patients with an adequate serologic treatment response.
ABSTRACT
We report a case of probable Zaire Ebola virus-related ophthalmologic complications in a physician from the United States who contracted Ebola virus disease in Liberia. Uveitis, immune activation, and nonspecific increase in antibody titers developed during convalescence. This case highlights immune phenomena that could complicate management of Ebola virus disease-related uveitis during convalescence.
